NASDAQ:TRDA

Entrada Therapeutics (TRDA) Stock Forecast, Price & News

$15.80

-0.38 (-2.35%)

(As of 09/29/2023 ET)

Compare

Today's Range: $15.56
▼
$16.41
50-Day Range: $13.61
▼
$17.37
52-Week Range: $9.32
▼
$24.38

Volume: 30,692 shs
Average Volume: 68,952 shs
Market Capitalization: $524.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.50

Entrada Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 37.3% Upside
$21.50 Price Target
Short Interest: Bearish
8.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.73
Based on 2 Articles This Week
Insider Trading: Selling Shares
$505,297 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.07) to ($2.35) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

879th out of 972 stocks

Pharmaceutical Preparations Industry

412th out of 451 stocks

3.3

Analyst's Opinion

Consensus Rating
Entrada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.50, Entrada Therapeutics has a forecasted upside of 37.3% from its current price of $15.66.
Amount of Analyst Coverage
Entrada Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.63% of the float of Entrada Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Entrada Therapeutics has a short interest ratio ("days to cover") of 26.1, which indicates bearish sentiment.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Entrada Therapeutics does not currently pay a dividend.
Dividend Growth
Entrada Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TRDA.

2.1

News and Social Media Coverage

News Sentiment
Entrada Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Entrada Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $505,297.00 in company stock.
Percentage Held by Insiders
Only 7.58% of the stock of Entrada Therapeutics is held by insiders.
Percentage Held by Institutions
77.59% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Entrada Therapeutics are expected to decrease in the coming year, from ($2.07) to ($2.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Entrada Therapeutics is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Entrada Therapeutics is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Entrada Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

TRDA Price History

30 days | 90 days | 365 days | Advanced Chart

TRDA Stock News Headlines

September 24, 2023 | americanbankingnews.com

Entrada Therapeutics (NASDAQ:TRDA) Rating Reiterated by HC Wainwright

September 21, 2023 | finance.yahoo.com

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

September 29, 2023 | Weiss Ratings (Ad)

Overlooked AI Stock Gets Urgent "Buy"

We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.

September 17, 2023 | barrons.com

Entrada Therapeutics Inc.

September 16, 2023 | finance.yahoo.com

Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares

September 12, 2023 | bizjournals.com

Good News Tuesday: Entrada Therapeutics supports initiatives to help those with Duchenne Muscular Dystrophy

September 7, 2023 | finance.yahoo.com

Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community

August 29, 2023 | finance.yahoo.com

Entrada Therapeutics to Present at Upcoming Investor Conferences

September 29, 2023 | Altimetry (Ad)

Seven millionaires secretly enable market shock?

A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.

August 10, 2023 | finance.yahoo.com

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

August 9, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)

August 8, 2023 | finance.yahoo.com

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

August 8, 2023 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates

August 4, 2023 | finance.yahoo.com

Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year

August 3, 2023 | seekingalpha.com

Entrada Therapeutics: Early Stage But Interesting

August 2, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Entrada Therapeutics Inc (TRDA) and Minerva Neurosciences (NERV)

August 1, 2023 | finance.yahoo.com

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

June 6, 2023 | finance.yahoo.com

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 24, 2023 | msn.com

HC Wainwright & Co. Reiterates Entrada Therapeutics (TRDA) Buy Recommendation

May 24, 2023 | markets.businessinsider.com

Entrada Therapeutics Inc (TRDA) Receives a Buy from H.C. Wainwright

May 15, 2023 | finance.yahoo.com

Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates

May 13, 2023 | finance.yahoo.com

Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

May 12, 2023 | seekingalpha.com

Entrada Therapeutics Stock Deserves Higher Resonance After Q1 2023 Report

May 11, 2023 | marketwatch.com

8-K: Entrada Therapeutics, Inc.

May 11, 2023 | markets.businessinsider.com

Goldman Sachs Sticks to Its Hold Rating for Entrada Therapeutics Inc (TRDA)

May 10, 2023 | finanznachrichten.de

Entrada Therapeutics, Inc.: Entrada Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023 | finance.yahoo.com

Entrada Therapeutics Reports First Quarter 2023 Financial Results

See More Headlines

Receive TRDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRDA Company Calendar

Last Earnings: 8/08/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TRDA
CUSIP: N/A
CIK: 1689375
Web: www.entradatx.com
Phone: 857-520-9158
Fax: N/A
Employees: 131
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.50
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +32.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-94,620,000.00
Net Margins: N/A
Pretax Margin: -149.60%
Return on Equity: -37.34%
Return on Assets: -22.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.10
Quick Ratio: 3.10

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.77 per share
Price / Book: 2.39

Miscellaneous

Outstanding Shares: 33,200,000
Free Float: 30,681,000
Market Cap: $537.18 million
Optionable: Not Optionable
Beta: -0.32

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Dipal Doshi (Age 47)
Pres, CEO & Director
Comp: $902.08k

Mr. Nathan J. Dowden (Age 52)
Chief Operating Officer
Comp: $654.6k

Dr. Natarajan Sethuraman Ph.D. (Age 61)
Chief Scientific Officer
Comp: $654.6k

Mr. Kory James Wentworth CPA (Age 43)
CFO & Treasurer

Dr. Jared Cohen J.D.
Ph.D., Gen. Counsel

Ms. Kerry Robert M.S.
Sr. VP of People

Dr. Nerissa C. Kreher M.B.A. (Age 50)
M.D., M.S., Chief Medical Officer

Ms. Karla MacDonald
Chief Corp. Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TRDA Stock - Frequently Asked Questions

Should I buy or sell Entrada Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TRDA shares.
View TRDA analyst ratings or view top-rated stocks.
What is Entrada Therapeutics' stock price forecast for 2023?: 3 brokerages have issued 12 month price objectives for Entrada Therapeutics' stock. Their TRDA share price forecasts range from $18.00 to $25.00. On average, they expect the company's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price.
View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts.
How have TRDA shares performed in 2023?: Entrada Therapeutics' stock was trading at $13.52 at the beginning of 2023. Since then, TRDA stock has increased by 19.7% and is now trading at $16.18.
View the best growth stocks for 2023 here.
When is Entrada Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our TRDA earnings forecast.
How were Entrada Therapeutics' earnings last quarter?: Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.35. The company had revenue of $18.17 million for the quarter, compared to the consensus estimate of $19.56 million.
When did Entrada Therapeutics IPO?: (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share.

What is Entrada Therapeutics' stock symbol?: Entrada Therapeutics trades on the NASDAQ under the ticker symbol "TRDA."
How do I buy shares of Entrada Therapeutics?: Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Entrada Therapeutics' stock price today?: One share of TRDA stock can currently be purchased for approximately $16.18.
How much money does Entrada Therapeutics make?: Entrada Therapeutics (NASDAQ:TRDA) has a market capitalization of $537.18 million. The company earns $-94,620,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.
How many employees does Entrada Therapeutics have?: The company employs 131 workers across the globe.
How can I contact Entrada Therapeutics?: The official website for the company is www.entradatx.com. The company can be reached via phone at 857-520-9158 or via email at investors@entradatx.com.

This page (NASDAQ:TRDA) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial